Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
Molecular Disease Profile of Hematological Malignancies
|3||Active, not recruiting||
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
† Study has passed its completion date and status has not been verified in more than two years.